Go to content

COVID-19: Medicago's Development Programs

Frequently Asked Questions (FAQ)

  1. Is Medicago publicly traded? Can I buy its shares?
    Medicago is not publicly traded and has been privately held since 2013.
     
  2. How can I volunteer for the human clinical trials?
    At this stage, we are performing pre-clinical studies and it is too early to communicate any information related to human trials enrollment.
     
  3. When will the COVID-19 vaccine be available?
    Depending on ongoing discussion with regulatory authorities, Medicago expects to initiate human trials by this summer (July/August 2020) with the objective of completing the development program and submitting a dossier to authorities by the end of next year (November 2021). The vaccine should be available after approval from respective regulatory authorities.
     

We invite you to subscribe to our newsletters below to be the first to receive our updates.

Want to be the first to know about Medicago news?

Sign up for our newsletter.

COVID-19 Vaccine

Development Program

On March 12, 2020, Medicago announced the successful production of Virus-Like Particle (VLPs) of the coronavirus just 20 days after obtaining the SARS-CoV-2 (virus causing the COVID-19 disease) gene. Production of VLPs is the first step in developing a vaccine against COVID-19 before preclinical testing for safety and efficacy.

VLPs mimic the native structure of viruses, allowing them to be easily recognized by the immune system. However, they lack core genetic material which makes them non-infectious and unable to replicate.

The photos below were taken using an electron microscopy to illustrate the similarity of Medicago's Coronavirus VLP with a wild-type SARS-CoV-2 virus:

Medicago's Plant-Derived Virus-Like Particle (VLP) of SARS-CoV-2

Depending on ongoing discussion with regulatory authorities, Medicago expects to initiate human trials by this summer (July/August 2020) for its COVID-19 vaccine candidate, with the objective of completing the development program and submitting a dossier to authorities by the end of next year (November 2021). This research is being partially funded by the Governments of Canada and Quebec.

COVID-19 Antibody

Development Program

In addition to the vaccine program, Medicago is using its technology platform to develop antibodies against SARS-CoV-2 in collaboration with the Laval University's Infectious Disease Research Centre. These SARS-CoV-2 antibodies could potentially be used to treat people infected by the virus. This research is being partially funded by the Canadian Institutes for Health Research (CIHR).

Disclaimer: These vaccine and antibody candidates are not approved for human use in ANY country or region and are currently under pre-clinical investigation.

Our VLP vaccine candidate for the coronavirus is currently in pre-clinical studies and the antibody is at the stage of research and development. We will investigate the safety and efficacy of these products when they reach the clinical stage of evaluation.

We invite you to subscribe to our newsletters below to be the first to receive our updates.

Want to be the first to know about Medicago news?

Sign up for our newsletter.